ART

Sponsor: University of Oxford
Clinical Trials.gov Number: NCT02145416

Anal squamous cell carcinoma: Investigation of functional imaging during Chemoradiotherapy (CRT)

Study Design

A single centre observational study to evaluate changes in functional images (MRI, Perfusion - CT, & FDG PET) after treatment with chemoradiotherapy.

Study Population

Patients undergoing radical CRT for anal cancer in Oxford University Hospitals NHS Trust.

CHARIOT

ATR inhibitor and chemoradiotherapy in oesophageal cancer.

This study will test the combination of a novel ATR inhibitor with radiotherapy or chemoradiotherapy in oesophageal cancer. The design is a phase I, open-label, multicentre, 3-stage, schedule-finding trial using TiTE-CRM (Time-to-Event Continual Reassessment Method).

The study is in setup with a planned opening date of May 2016. A CRUK New Agents Committee grant has been awarded for this study (CRUKD/15/011). Site selection will include Oxford, Leeds & Glasgow.

Nicola Sibson

Our goals are to identify the role of the inflammatory and metabolic microenvironment in brain metastasis, and to develop imaging biomarkers for tumour detection and monitoring.

Pages

About Us
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
Research
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate training programmes for both scientists and clinicians are internationally recognised.
Subscribe to Department of Oncology RSS